GILDGilead Sciences, Inc.
# 73 · $156.04 (-0.73%) · $193.48B · Healthcare
Rango 52 semanas
Datos de mercado
- P/E
- —
- 1M
- +4.24%
- 1A
- +32.43%
- Rentab.
- 2.08%
- RSI
- 66.07
- MACD
- +0.29%
Desglose
Por qué
- earnings growth of +22.6% a year over 2 years (+1672.9% in the latest year alone, inflated by an unusually low prior year)
- margin and ROA expanding YoY
- 12-1 momentum return of 27.0%
- trading 13.4% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +7.9% on average
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
8
8 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Altman Z in grey zoneMedia
Z-Score 1.94 (1.81–2.99) — not clearly safe
- Loss-makingMedia
net margin -10.6%
- High leverageMedia
debt/equity 222% (alert threshold 200%)
- Geographic revenue concentrationInfo
71% of revenue from United States
- Product revenue concentrationInfo
98% of revenue from Products
Análisis de la empresa
Business Overview Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines, with core franchises in HIV, liver disease/viral hepatitis, oncology, and COVID-19 therapeutics; it generates revenue primarily from product sales to wholesalers/distributors and directly to certain institutions, plus smaller amounts of royalty/other revenue. Market Position Gilead is a leading global player in HIV antiretroviral therapy, anchored by Biktarvy and a broader HIV portfolio, and competes in oncology with Trodelvy and Kite cell therapies (Yescarta, Tecartus), while Veklury contributes COVID-19-related revenue that has been more variable with hospitalization trends. Key Segments Gilead reports major product areas including HIV, Liver Disease, Oncology, and Veklury (remdesivir).
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31